| Ultra-fast excited state dynamics in green fluorescent protein: multiple states and proton transfer. M Chattoraj, BA King, GU Bublitz, SG Boxer Proceedings of the National Academy of Sciences 93 (16), 8362-8367, 1996 | 1069 | 1996 |
| JAK inhibitors in dermatology: the promise of a new drug class W Damsky, BA King Journal of the American Academy of Dermatology 76 (4), 736-744, 2017 | 486 | 2017 |
| Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials EL Simpson, JP Lacour, L Spelman, R Galimberti, LF Eichenfield, ... British Journal of Dermatology 183 (2), 242-255, 2020 | 394 | 2020 |
| Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata MK Crispin, JM Ko, BG Craiglow, S Li, G Shankar, JR Urban, JC Chen, ... JCI insight 1 (15), 2016 | 340 | 2016 |
| Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients LY Liu, BG Craiglow, F Dai, BA King Journal of the American Academy of Dermatology 76 (1), 22-28, 2017 | 337 | 2017 |
| Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy BG Craiglow, BA King JAMA dermatology 151 (10), 1110-1112, 2015 | 308 | 2015 |
| A neutrophil activation signature predicts critical illness and mortality in COVID-19 ML Meizlish, AB Pine, JD Bishai, G Goshua, ER Nadelmann, M Simonov, ... Blood advances 5 (5), 1164-1177, 2021 | 287 | 2021 |
| Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis BG Craiglow, BA King J invest dermatol 134 (12), 2988-2990, 2014 | 259 | 2014 |
| Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate LL Levy, J Urban, BA King Journal of the American Academy of Dermatology 73 (3), 395-399, 2015 | 247 | 2015 |
| Two phase 3 trials of baricitinib for alopecia areata B King, M Ohyama, O Kwon, A Zlotogorski, J Ko, NA Mesinkovska, ... New England Journal of Medicine 386 (18), 1687-1699, 2022 | 237 | 2022 |
| Crystal structure and photodynamic behavior of the blue emission variant Y66H/Y145F of green fluorescent protein RM Wachter, BA King, R Heim, K Kallio, RY Tsien, SG Boxer, ... Biochemistry 36 (32), 9759-9765, 1997 | 228 | 1997 |
| Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure LY Liu, JP Strassner, MA Refat, JE Harris, BA King Journal of the American Academy of Dermatology 77 (4), 675-682. e1, 2017 | 199 | 2017 |
| Tofacitinib for the treatment of alopecia areata and variants in adolescents BG Craiglow, LY Liu, BA King Journal of the American Academy of Dermatology 76 (1), 29-32, 2017 | 185 | 2017 |
| Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review LY Liu, BA King, BG Craiglow Journal of the American Academy of Dermatology 75 (4), 806-812. e3, 2016 | 168 | 2016 |
| Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series R Abdat, RA Waldman, V de Bedout, A Czernik, M Mcleod, B King, ... Journal of the American Academy of Dermatology 83 (1), 46-52, 2020 | 152 | 2020 |
| Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis W Damsky, D Thakral, N Emeagwali, A Galan, B King New England Journal of Medicine 379 (26), 2540-2546, 2018 | 147 | 2018 |
| The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata N Meah, D Wall, K York, B Bhoyrul, L Bokhari, DA Sigall, WF Bergfeld, ... Journal of the American Academy of Dermatology 83 (1), 123-130, 2020 | 144 | 2020 |
| Atypical hand-foot-and-mouth disease associated with coxsackievirus A6 infection JP Lott, K Liu, ML Landry, WA Nix, MS Oberste, J Bolognia, B King Journal of the American Academy of Dermatology 69 (5), 736-741, 2013 | 134 | 2013 |
| Topical ruxolitinib for the treatment of alopecia universalis BG Craiglow, D Tavares, BA King JAMA dermatology 152 (4), 490-491, 2016 | 120 | 2016 |
| A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24 … B King, E Guttman-Yassky, E Peeva, A Banerjee, R Sinclair, AB Pavel, ... Journal of the American Academy of Dermatology 85 (2), 379-387, 2021 | 116 | 2021 |
Christopher BunickYale UniversityVerified email at yale.edu
Christopher BunickYale UniversityVerified email at yale.edu